SME Times is powered by   
Search News
Just in:   • India's 52-satellite initiative to enhance surveillance  • Egyptian, French FMs discuss developments in Lebanon, Gaza  • Mysore-Darbhanga Bagmati Express derails in Tamil Nadu; many injured  • India's industrial production sees marginal contraction, manufacturing production rises  • Centre notifies guidelines for ‘Innovative Projects’ under PM Surya Ghar Yojana 
Last updated: 26 Sep, 2024  

pharma-222 India’s pharmaceutical sector projected to reach $130 billion by 2030

pharma
   Top Stories
» Centre notifies guidelines for ‘Innovative Projects’ under PM Surya Ghar Yojana
» Middle East tensions, high crude oil prices bring rupee to 84-mark against dollar
» India’s ship recycling industry expected to grow at 10 pc CAGR by 2028
» Noel Tata appointed Chairman of Tata Trusts
» Doyen of India Inc, Tata Group's Ratan Tata passes away
IANS | 26 Sep, 2024

 India is on the cusp of a transformative era in its pharmaceutical sector which is projected to reach $130 billion by 2030, a report showed on Thursday.

The world's third-largest drug producer by volume, India is currently exporting pharmaceutical products to over 200 countries, establishing its influence in the global pharmaceutical arena, according to a Deloitte's whitepaper launched at the Assocham’s annual pharma summit here.

The paper highlighted India's potential to transform from a leading generic drug producer to a powerhouse of pharmaceutical innovation, driven by advancements in research, regulatory reforms, and strategic global partnerships.

“With the market projected to reach $130 billion by 2030, growth depends on significant investments in R&D and addressing talent shortages in areas like AI and biotechnology,” said Joydeep Ghosh, Partner and Industry Leader for Life Sciences and Healthcare at Deloitte India.

Government initiatives such as the production-linked incentive scheme aim to enhance domestic manufacturing and reduce reliance on imports.

“By fostering collaboration among academia, industry, and government, India can not only meet its healthcare needs but also position itself as a leader in global pharmaceutical innovation, driving economic growth and improving health outcomes,” Ghosh added.

As per the paper, with a growing talent pool, rising investments in biotechnology, and an increasing number of clinical trials, India is becoming a credible destination for cutting-edge drug discovery and development.

Government initiatives, collaborations between academia and industry, and advancements in digital technologies further bolster India's potential to lead in pharmaceutical innovation.

However, the paper identified critical challenges that must be addressed to fully realise India's potential as a global pharmaceutical innovation hub.

“Key issues include the need for increased investment in R&D, stronger intellectual property protections, and the closing of the talent gap in high-demand areas such as artificial intelligence and data science,” the paper noted.

To foster a robust innovation ecosystem, it is crucial to develop a cohesive strategy that integrates research, technology investments, commercialization, skilling, and intellectual property, commented Neha Aggarwal, Partner, Deloitte India.

 
Print the Page
Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
84.35
82.60
UK Pound
106.35
102.90
Euro
92.50
89.35
Japanese Yen 55.05 53.40
As on 12 Oct, 2024
  Daily Poll
Will the new MSME credit assessment model simplify financing?
 Yes
 No
 Can't say
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter